Cash, cash equivalents and short-term investments were $96.5M as of December 31, 2023, compared to $117.1M as of September 30, 2023, and $185.6M as of December 31, 2022. “We have made tremendous progress during 2023 and in 2024 to date in our development of Ixo-vec as a durable potential gene therapy treatment for the millions of patients suffering from wet AMD,” stated Laurent Fischer, president and chief executive officer of Adverum Biotechnologies. “We were pleased to present at Macula Society preliminary data from our ongoing LUNA Phase 2 trial of Ixo-vec, which demonstrated potentially best-in-class clinical activity at both the 2E11 and 6E10 doses of Ixo-vec, with the data trending similar to, or better than, the data in our first-in-human OPTIC trial. Importantly, the preliminary data demonstrated that Ixo-vec was generally well tolerated. We look forward to presenting the 26-week interim analysis of our LUNA Phase 2 program in mid-2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADVM:
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
- Adverum Biotechnologies files to sell 106.48M shares of common stock for holders
- ADVM Upcoming Earnings Report: What to Expect?
- Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
- Adverum’s Ixoberogene Soroparvovec Shows Promise in LUNA Trial